The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Exocrine Pancreatic Insufficiency-Global Market Insights and Sales Trends 2024
Synopsis
Exocrine pancreatic insufficiency (EPI) is an inability of proper digestion of food owing to insufficient levels of digestive enzymes from pancreas.
The global Exocrine Pancreatic Insufficiency market size is expected to reach US$ 2644.6 million by 2029, growing at a CAGR of 3.9% from 2023 to 2029. The market is mainly driven by the significant applications of Exocrine Pancreatic Insufficiency in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Exocrine Pancreatic Insufficiency market. Therapeutics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Diagnostics segment is estimated at % CAGR for the next seven-year period.
EPI is commonly found in humans affected with Shwachman-Diamond Syndrome and cystic fibrosis. EPI is triggered by the progressive loss of pancreatic cells, which generates the digestive enzymes. EPI disturbs the normal growth, life expectancy and immune response. Diarrhoea, Steatorrhea, fatigue and weight loss are the key symptoms of EPI.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Exocrine Pancreatic Insufficiency, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Exocrine Pancreatic Insufficiency market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Exocrine Pancreatic Insufficiency market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Exocrine Pancreatic Insufficiency sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Exocrine Pancreatic Insufficiency covered in this report include Axcan Pharma, Aptalis Pharma, Eli Lilly, Cilian, Nordmark Arzneimittel and Laboratoires Mayoly Spindler, etc.
The global Exocrine Pancreatic Insufficiency market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Axcan Pharma
Aptalis Pharma
Eli Lilly
Cilian
Nordmark Arzneimittel
Laboratoires Mayoly Spindler
Global Exocrine Pancreatic Insufficiency market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Exocrine Pancreatic Insufficiency market, Segment by Type:
Therapeutics
Diagnostics
Global Exocrine Pancreatic Insufficiency market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Exocrine Pancreatic Insufficiency companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Exocrine pancreatic insufficiency (EPI) is an inability of proper digestion of food owing to insufficient levels of digestive enzymes from pancreas.
The global Exocrine Pancreatic Insufficiency market size is expected to reach US$ 2644.6 million by 2029, growing at a CAGR of 3.9% from 2023 to 2029. The market is mainly driven by the significant applications of Exocrine Pancreatic Insufficiency in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Exocrine Pancreatic Insufficiency market. Therapeutics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Diagnostics segment is estimated at % CAGR for the next seven-year period.
EPI is commonly found in humans affected with Shwachman-Diamond Syndrome and cystic fibrosis. EPI is triggered by the progressive loss of pancreatic cells, which generates the digestive enzymes. EPI disturbs the normal growth, life expectancy and immune response. Diarrhoea, Steatorrhea, fatigue and weight loss are the key symptoms of EPI.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Exocrine Pancreatic Insufficiency, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Exocrine Pancreatic Insufficiency market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Exocrine Pancreatic Insufficiency market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Exocrine Pancreatic Insufficiency sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Exocrine Pancreatic Insufficiency covered in this report include Axcan Pharma, Aptalis Pharma, Eli Lilly, Cilian, Nordmark Arzneimittel and Laboratoires Mayoly Spindler, etc.
The global Exocrine Pancreatic Insufficiency market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Axcan Pharma
Aptalis Pharma
Eli Lilly
Cilian
Nordmark Arzneimittel
Laboratoires Mayoly Spindler
Global Exocrine Pancreatic Insufficiency market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Exocrine Pancreatic Insufficiency market, Segment by Type:
Therapeutics
Diagnostics
Global Exocrine Pancreatic Insufficiency market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Exocrine Pancreatic Insufficiency companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Exocrine Pancreatic Insufficiency
1.1 Exocrine Pancreatic Insufficiency Market Overview
1.1.1 Exocrine Pancreatic Insufficiency Product Scope
1.1.2 Exocrine Pancreatic Insufficiency Market Status and Outlook
1.2 Global Exocrine Pancreatic Insufficiency Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Exocrine Pancreatic Insufficiency Market Size by Region (2018-2029)
1.4 Global Exocrine Pancreatic Insufficiency Historic Market Size by Region (2018-2023)
1.5 Global Exocrine Pancreatic Insufficiency Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Exocrine Pancreatic Insufficiency Market Size (2018-2029)
1.6.1 North America Exocrine Pancreatic Insufficiency Market Size (2018-2029)
1.6.2 Europe Exocrine Pancreatic Insufficiency Market Size (2018-2029)
1.6.3 Asia-Pacific Exocrine Pancreatic Insufficiency Market Size (2018-2029)
1.6.4 Latin America Exocrine Pancreatic Insufficiency Market Size (2018-2029)
1.6.5 Middle East & Africa Exocrine Pancreatic Insufficiency Market Size (2018-2029)
2 Exocrine Pancreatic Insufficiency Market by Type
2.1 Introduction
2.1.1 Therapeutics
2.1.2 Diagnostics
2.2 Global Exocrine Pancreatic Insufficiency Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Exocrine Pancreatic Insufficiency Historic Market Size by Type (2018-2023)
2.2.2 Global Exocrine Pancreatic Insufficiency Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Exocrine Pancreatic Insufficiency Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Exocrine Pancreatic Insufficiency Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Exocrine Pancreatic Insufficiency Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Exocrine Pancreatic Insufficiency Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Exocrine Pancreatic Insufficiency Revenue Breakdown by Type (2018-2029)
3 Exocrine Pancreatic Insufficiency Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Exocrine Pancreatic Insufficiency Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Exocrine Pancreatic Insufficiency Historic Market Size by Application (2018-2023)
3.2.2 Global Exocrine Pancreatic Insufficiency Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Exocrine Pancreatic Insufficiency Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Exocrine Pancreatic Insufficiency Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Exocrine Pancreatic Insufficiency Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Exocrine Pancreatic Insufficiency Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Exocrine Pancreatic Insufficiency Revenue Breakdown by Application (2018-2029)
4 Exocrine Pancreatic Insufficiency Competition Analysis by Players
4.1 Global Exocrine Pancreatic Insufficiency Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Exocrine Pancreatic Insufficiency as of 2022)
4.3 Date of Key Players Enter into Exocrine Pancreatic Insufficiency Market
4.4 Global Top Players Exocrine Pancreatic Insufficiency Headquarters and Area Served
4.5 Key Players Exocrine Pancreatic Insufficiency Product Solution and Service
4.6 Competitive Status
4.6.1 Exocrine Pancreatic Insufficiency Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Axcan Pharma
5.1.1 Axcan Pharma Profile
5.1.2 Axcan Pharma Main Business
5.1.3 Axcan Pharma Exocrine Pancreatic Insufficiency Products, Services and Solutions
5.1.4 Axcan Pharma Exocrine Pancreatic Insufficiency Revenue (US$ Million) & (2018-2023)
5.1.5 Axcan Pharma Recent Developments
5.2 Aptalis Pharma
5.2.1 Aptalis Pharma Profile
5.2.2 Aptalis Pharma Main Business
5.2.3 Aptalis Pharma Exocrine Pancreatic Insufficiency Products, Services and Solutions
5.2.4 Aptalis Pharma Exocrine Pancreatic Insufficiency Revenue (US$ Million) & (2018-2023)
5.2.5 Aptalis Pharma Recent Developments
5.3 Eli Lilly
5.3.1 Eli Lilly Profile
5.3.2 Eli Lilly Main Business
5.3.3 Eli Lilly Exocrine Pancreatic Insufficiency Products, Services and Solutions
5.3.4 Eli Lilly Exocrine Pancreatic Insufficiency Revenue (US$ Million) & (2018-2023)
5.3.5 Cilian Recent Developments
5.4 Cilian
5.4.1 Cilian Profile
5.4.2 Cilian Main Business
5.4.3 Cilian Exocrine Pancreatic Insufficiency Products, Services and Solutions
5.4.4 Cilian Exocrine Pancreatic Insufficiency Revenue (US$ Million) & (2018-2023)
5.4.5 Cilian Recent Developments
5.5 Nordmark Arzneimittel
5.5.1 Nordmark Arzneimittel Profile
5.5.2 Nordmark Arzneimittel Main Business
5.5.3 Nordmark Arzneimittel Exocrine Pancreatic Insufficiency Products, Services and Solutions
5.5.4 Nordmark Arzneimittel Exocrine Pancreatic Insufficiency Revenue (US$ Million) & (2018-2023)
5.5.5 Nordmark Arzneimittel Recent Developments
5.6 Laboratoires Mayoly Spindler
5.6.1 Laboratoires Mayoly Spindler Profile
5.6.2 Laboratoires Mayoly Spindler Main Business
5.6.3 Laboratoires Mayoly Spindler Exocrine Pancreatic Insufficiency Products, Services and Solutions
5.6.4 Laboratoires Mayoly Spindler Exocrine Pancreatic Insufficiency Revenue (US$ Million) & (2018-2023)
5.6.5 Laboratoires Mayoly Spindler Recent Developments
6 North America
6.1 North America Exocrine Pancreatic Insufficiency Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Exocrine Pancreatic Insufficiency Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Exocrine Pancreatic Insufficiency Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Exocrine Pancreatic Insufficiency Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Exocrine Pancreatic Insufficiency Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Exocrine Pancreatic Insufficiency Market Dynamics
11.1 Exocrine Pancreatic Insufficiency Industry Trends
11.2 Exocrine Pancreatic Insufficiency Market Drivers
11.3 Exocrine Pancreatic Insufficiency Market Challenges
11.4 Exocrine Pancreatic Insufficiency Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
